It is one of the odder aspects of biotech life that one of the most important new ways to increase the dealmaking value of products has nothing to do with biology, medicine, the stock market, medical practice, or even negotiating—but sales auditing.
Consider: one of 2005's best-performing IPOs came from Aspreva Pharmaceuticals Corp. which bases its business on securing approvals for...